Literature DB >> 28640653

Epithelial-Mesenchymal Transition: A Necessary New Therapeutic Target in Chronic Obstructive Pulmonary Disease?

Sukhwinder Singh Sohal1, Mathew Suji Eapen2, Chris Ward2,3, Eugene Haydn Walters2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28640653     DOI： 10.1164/rccm.201704-0771LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  4 in total

Review 1.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

2.  Increased myofibroblasts in the small airways, and relationship to remodelling and functional changes in smokers and COPD patients: potential role of epithelial-mesenchymal transition.

Authors:  Mathew Suji Eapen; Wenying Lu; Tillie L Hackett; Gurpreet Kaur Singhera; Malik Q Mahmood; Ashutosh Hardikar; Chris Ward; Eugene Haydn Walters; Sukhwinder Singh Sohal
Journal:  ERJ Open Res       Date:  2021-06-07

3.  Epithelial-mesenchymal transition is driven by transcriptional and post transcriptional modulations in COPD: implications for disease progression and new therapeutics.

Authors:  Mathew Suji Eapen; Pawan Sharma; Archana Vijay Gaikwad; Wenying Lu; Stephen Myers; Philip M Hansbro; Sukhwinder Singh Sohal
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-07-18

Review 4.  How Do Innate Immune Cells Contribute to Airway Remodeling in COPD Progression?

Authors:  Tegeleqi Bu; Li Fang Wang; Yi Qing Yin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-01-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.